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Long-term home oxygen therapy (LTOT) improves survival of hypoxic patients with chronic respiratory 
insufficiency. However, the health-related quality of life (HRQL) of these patients, when LTOT is 
initiated, is severely impaired. The present study aims to describe the health-related quality of life 
(HRQL) of patients under LTOT, assessed at home, to identify parameters relevant to HRQL, and to 
describe changes over a 1-yr period. 
Seventy-nine patients (aged 68 * 11 years, under LTOT for 34 X!Z 24 months) underwent pulmonary 
function testing, measurement of average daily distance walked, SaOZ, dyspnoea scores (Borg scale and 
oxygen-cost diagram), and Hospital Anxiety and Depression scores. After 1 yr, measurements were 
repeated, and HRQL was measured with the St George Respiratory Questionnaire (SGRQ). 
Forced expiratory volume in 1 s (FEV, % of predicted) was 36 f 19; SaO, (room air) was 87 f 5%; 
daily distance walked was 1202 * 1140 m; 21% suffered from anxiety and 27% from depression. After 
1 yr, pulmonary function tests, dyspnoea or prevalence of anxiety or depression were unchanged. 
Mortality was high (31% 1-yr mortality). Daily distance walked (rho= - 0.55, P=O.Ol vs. SGRQ) and 
number of days spent in hospital (rho=0.5, P=O.Ol vs. SGRQ) were the parameters with the highest 
correlation with HRQL scores. 
Quality of life was poor in these patients, with high rates of emotional disorders. Restoring and 
maintaining sufficient exercise capacity for everyday life activities through outpatient rehabilitation 
programmes and support for emotional disturbances should be major goals in the care of these patients. 
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Introduction 
Approximately 6% of the general population suffer 
from chronic obstructive pulmonary disease (COPD). 
Fifty percent of these patients have a limited activity 
related to their respiratory impairment (1,2). Of these, 
0.3% suffer from chronic hypoxaemia (estimated 
prevalence: 15-20 per 100 000 inhabitants); they have 
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a poor prognosis with a 2-yr survival of approxi- 
mately 50% (3). Long-term oxygen therapy (LTOT) 
was shown to clearly improve survival (3,4), pul- 
monary haemodynamics (5,6) and exercise capacity 
of these patients (7). Long-term oxygen therapy has 
thus become a standard and widely accepted treat- 
ment for stable hypoxic (~55 mmHg or 7.3 kPa) 
patients with chronic respiratory insufficiency (COPD 
and mixed or restrictive disorders). However, LTOT 
does not seem to diminish the average number or 
length of hospitalizations of hypoxic COPD patients; 
indeed, the Medical Research Council study (3) 
shows that number of days spent in hospital does not 
differ between patients under LTOT, and a control 
0 1997 W. B. SAUNDERS COMPANV LTD 
HEALTH-RELATEDQUALITYOFLIFEINPATIENTSUNDERLONG-TERMOXYGENTHERAPY 593 
group. This is an important issue since frequency 
and length of hospitalizations are most probably 
contributive to impaired quality of life. 
Furthermore, several authors suggest that, in 
contrast with a clear benefit on survival, and physio- 
logical parameters, LTOT causes only modest 
improvements in neuropsychological functioning - 
impaired in chronic hypoxic respiratory disease - 
and does not seem to bring any appreciable change in 
emotional status or general life quality (8,9). This is 
also a most important issue, since available studies 
describe a high level of emotional and mood distur- 
bances in hypoxic COPD and generic scores of quality 
of life show a severe impairment for these patients in 
most domains tested (8,10-12). 
The aim of the present study is to describe 
the health-related quality of the life (HRQL) of 
patients under LTOT directly assessed at home, to 
determine the prevalence of emotional disturbances 
in this group of patients, to identify parameters 
possibly relevant to HRQL through the use of 
disease-specific HRQL instruments, and to analyse 
the changes in these items over a I-yr observation 
period. 
Patients and Methods 
This study was conducted in the Canton of Valais, an 
area in the Swiss Alps with a population of 270 000 
inhabitants. All patients under LTOT in this area 
have been evaluated by a referral centre (Centre 
Valaisan de Pneumologie, Crans-Montana) and have 
received a 2-day training regarding LTOT (13); they 
were all hypoxaemic under room air (PaO, 
~55 mmHg or 7.3 kPa)‘ when LTOT was started; 
specialized nurses visited the patients at home, for 
clinical assessment and monitoring of compliance, at 
approximately 3-monthly intervals. 
PATIENTS (DATA EXPRESSED AS MEAN f SD) 
This study began on 1 March 1994; at that date, 123 
patients were under LTOT. Seventy-nine patients (52 
men, 27 women, aged 68 & 11 years, range: 15-86) 
agreed to participate to the present study. These 
patients had been under LTOT for 34 + 24 months 
(median: 24 range: 2-106) for 15 *4.5 h day-‘. 
Diagnoses are listed in Table 1. None of these 
patients had received antibiotics or been hospitalized 
for exacerbation of respiratory symptoms within 1 
month before evaluation. Forty-one patients (54%) 
had been hospitalized within the past year (mean 
length of stay for these patients: 51 f 53 days, n=41). 
Thirteen patients (16%) were active smokers, 42 
TABLE 1. Diagnoses of patients included in study 
n=79 Oh 
Chronic obstructive pulmonary disease 50 63 
Restrictive disorders 12 15 
Bronchiectasis 3 
Sarcoidosis 2 
Kyphoscoliosis 3 
Pulmonary fibrosis 2 
Farmer’s lung 2 
Mixed disorders 11 14.5 
Pulmonary hypertension 4 5 
Other 2 2.5 
ex-smokers (54%) and 24 non-smokers (30%). (Active 
smoking is considered as a contra-indication to 
LTOT: patients currently smoking had resumed their 
habit after initiation of LTOT.) Average body-mass 
index was: 24.4 4 5.2 kg m - 2, 25% of patients 
were malnourished (weight ~90% of ideal body 
weight) (14). 
Of the initial 123 patients, 35 men (60 ZIZ 21 years of 
age) and nine women (74 f 8 years of age) were not 
included. Thirty-four patients declined to enter the 
present study (27%); eight patients (6%) died before 
evaluation could be performed, and two stopped 
LTOT. 
PULMONARY FUNCTION TESTING 
Spirometric measurements were performed with a 
Vitalograph C@ (Compact spirometer, Maids 
Moreton House, Buckinghamshire, U.K.), according 
to the recommendations of the American Thoracic 
Society (15). The best of at least three consecutive 
measurements were recorded. The spirometer was 
recalibrated with a calibration syringe (Model M20, 
Gould, Dayton, U.S.A.) before performing measure- 
ments for every new patient. Forced expiratory vol- 
ume in 1 s (FEV,), forced vital capacity (FVC), and 
FEV,/FVC are expressed as a percentage of predicted 
values. 
Maximal inspiratory and expiratory pressures were 
measured with a Mouth Pressure Meter@ (Precision 
Medical Ltd, Thornton Rd. Ind. Est., Pickering 
U.K.), recently validated by Hamnegard et al. (16). 
Peak inspiratory pressures (PI max) were measured at 
residual volume, and peak expiratory mouth pres- 
sures (PE max) were measured at total lung capacity. 
Three to six manoeuvres were done with the goal 
of the highest two matching within 10%. Data 
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were discarded if the pressure was held less than 1 s 
(the Mouth Pressure Meter@ has an integrated 
software which auto-calibrates, and eliminates short 
samples) (17). 
Blood oxygen saturation was measured with a 
portable pulse oximeter (BCI 3301@, Rockwood 
Drive, Waukesha, WI, U.S.A.). Measurements were 
recorded under room air conditions, after at least 
15 min of resting, and under prescribed flow of 
oxygen, after 15 min. 
MEASUREMENT OF AVERAGE DAILY 
DISTANCE WALKED 
Each patient received a podometer (Kilometer- 
zahler@, K & R, Freiburg, Germany), and was asked 
to wear it attached to his waist for 7 consecutive days. 
The podometer records the oscillations caused by 
each step, and transcribes them into metres walked. 
Individual calibration was performed by having 
patients walk 20 m, calculating the mean length of 
step, and reporting this value on a scale on the 
podometer. 
ASSESSMENT OF DYSPNOEA (FIGS 1 AND 2) 
Resting dyspnoea was scored using a modified Borg 
scale. Data are expressed on a O-10 scale (O=minimal 
dyspnoea, lO=maximal dyspnoea) (l&19). 
An oxygen-cost diagram was used to quantify the 
effort above which patients thought their breathless- 
ness would not allow them to go; results are also 
expressed in millimetres (O=maximal impairment, 
lOO=no impairment) (20). 
HEALTH-RELATED QUALITY OF LIFE 
INSTRUMENTS 
The ‘Hospital Anxiety and Depression’ questionnaire 
(HAD) was used to score for anxiety or depressive 
disorders: it contains 14 multiple choice-type ques- 
tions; seven questions are oriented towards detection 
of anxiety disorders and seven towards detection 
of depression. HAD has been validated in French 
(21). Answers are scored for ‘anxiety’ (HAD A) 
and ‘depression’ (HAD D), with scores ranging 
from 0 to 21 for each category. Zigmond et al. (22) 
describe scoring as follows: O-8, no evidence for 
depressive or anxiety disorders; S-10, borderline 
values suggestive of depression or anxiety; above 10, 
abnormal values with a high specificity for anxiety 
or depressive disorders: HAD scores 28 have a 
sensitivity and a specificity of 76% for diagnosing 
depressive disorders. Scores > 11 have a sensitivity 
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FIG. 1. Left: Borg scale used for measuring resting 
dyspnoea; Right: Values obtained in 79 patients. 
Horizontal bar indicates median value for Borg 
scale scores. 
of only 52%, but a specificity of 94%. For the 
present study, a cut-off value of 2 11 was used to 
define patients suffering from anxiety or depressive 
disorders. 
The St George Respiratory Questionnaire (SGRQ) 
was used for HRQL measurement at follow-up visit. 
(A validated version in French was not available at 
the beginning of this study). The SGRQ is a disease- 
specific HRQL measurement instrument which con- 
tains 76 items divided into three sections: ‘Symptoms’ 
relates to respiratory symptoms, their frequency and 
severity; ‘Activity’ relates to activities that cause or 
are limited by breathlessness; and ‘Impacts’ covers 
social functioning and psychological disturbances 
resulting from respiratory disease. A score is calcu- 
lated for each section, as well as’ a total score. A 
database of SGRQ scores for normal subjects without 
any history of respiratory disease (n= 74, mean age: 
46, range: 17-80, FEV, 95% predicted) is supplied by 
the authors of the SGRQ. Reference values for nor- 
mal subjects are 12 (range: 9-15) for ‘Symptoms’ 
score, 9 (range: 7-12) for ‘Activity’ score, 2 (range: 
l-3) for ‘Impacts’ score, and 6 (range: 5-7) for 
total score. Higher scores are related to increasing 
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FIG. 2. Left: Oxygen-cost diagram: the oxygen-cost diagram quantifies the maximum effort a patient can 
sustain without being limited by dyspnoea. Right: Results for 79 patients: horizontal bar indicates median value. 
impairment or severity of symptoms (range O-100) 
(23,24). The SGRQ has been recently validated in 
French by BrianGon et al. (25). 
Attending physicians were asked to quantify the 
quality of life of their patients by using a simple 
validated index [QL-index, Spitzer et al. (26)] which 
was sent to all attending physicians. This score con- 
sists of a visual analogue scale, with scores recorded 
between 0 (very poor) and 100 (excellent). 
RECORDING OF COMPLIANCE TO LTOT 
Visiting nurses kept 3-monthly records of oxygen 
extractor meters totalizing number of hours of effec- 
tive use. This allowed for calculation of average daily 
use, and estimation of compliance to treatment. Since 
all patients had been informed of the necessity of 
taking oxygen at least 15 h day - ’ during a short 48-h 
hospitalization (13), compliance to treatment was 
defined as the perdentage of patients using their 
oxygen extractors 2 15 h day - ‘. 
INITIAL EVALUATION 
All patients willing to participate in the present study 
were visited by the investigating physician and a 
registered nurse. Clinical assessment and all measure- 
ments were performed at the patient’s home. 
The initial examination covered: relevant medical 
history, physical examination, pulmonary function 
testing, assessment of dyspnoea, anthropometric 
measurements (body weight and height), average 
daily distance walked, health-related quality of life, 
and compliance to LTOT. 
FOLLOW-UP STUDY 
Approximately 1 yr after the initial evaluation, the 
investigating physician returned for a follow-up visit. 
The following parameters were measured during this 
second visit: FEV,, CVF, SaO, under room air and 
oxygen, body weight, average daily distance walked, 
dyspnoea ratings, Hospital Anxiety and Depression 
scores (HAD), and the St George Respiratory 
Questionnaire (SGRQ). 
STATISTICAL METHODS 
Results are expressed as mean & SD for parametric 
data or median with range as appropriate. Par- 
ameters measured initially and after follow-up period 
were compared by paired t-tests (parametric data), 
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Average daily distance walked (metres day-l) 
FIG. 3. Average daily distance walked per day, 
assessed by podometer worn over a 7-day period. 
or Wilcoxon’s signed rank test (non-parametric or 
ordinal data). For comparisons between groups of 
different individuals, the authors used unpaired t-tests 
for parametric data, Chi-squared analysis of contin- 
gency tables (expressed as x’) for nominal data (or 
Fisher’s test when indicated) and Mann-Whitney 
rank-sum test for ordinal data. Association between 
variables was tested by calculating Pearson’s 
product-moment correlation coefficient (expressed as 
r) for parametric data, and by computing Spearman’s 
Rank correlations for ordinal data (expressed as rho) 
(27). 
The present study was approved by the Medical 
Ethics Committee of the University Hospital of 
Geneva, Switzerland. 
Results 
INITIAL EVALUATION 
Dyspnoea scores (median, range) (Figs 1 and 2) 
Results for dyspnoea scores were: 2 (range: O-7) for 
resting dyspnoea (Borg scale) and 45 (range: 
21-71 mm) for exertional dyspnoea (oxygen-cost 
diagram). 
Pulmonary function tesfing (PFT) and average daily 
distance walked (Fig. 3; Table 2) 
Pulmonary function testing values are given in Table 
2. Average daily distance walked was: 1202 * 1139 m 
(median: 836, range: 304600); 19 patients (27%) 
walked less than 300 m day-‘; 36 patients (46%) 
walked less than 600 m day - ‘. 
HRQL scores (median, range) 
Median value for QL-index scores, reported by 
attending physicians was: 48 (range: 695). The rate 
of response by physicians was 84%. 
Hospital Anxiety and Depression (HAD) scores 
were: 6.5 (range:O-18) for anxiety and 6 (range: 1-17) 
for depression. This suggests a prevalence of anxiety 
disorders of 21% (n= 16) and of depressive disorders 
of 27% (n =21). Prevalence of HAD scores 2 11 did 
not differ between COPD and non-COPD patients. 
Compliance to treatment 
Patients were under oxygen for 15 & 4 h day - ’ 
(median f SD). Twenty-eight patients (35%) did not 
TABLE 2. Pulmonary function tests and average daily distance walked 
n=79 
Mean f SD Range 
FEV, (1) 0.88 It 0.44 (0.18-2.5) 
FEV, (% of predicted) 36 f 19 (8-l 13) 
CVF (1) 2,34 zt 0.92 (0.334.8) 
CVF (% of predicted) 72 f 27 (19-145) 
FEV,/CVF (% of predicted) 52 f 21 (15-103) 
PI max (cm H20)* 49zt 19 (12-106) 
PE max (cm H20)’ 80f31 (22-179) 
SaO,% (room air) 87 f 5 (70-96) 
SaOz% (oxygen as prescribed) 93 f 3 (83-98) 
Average daily distance walked (meters) 1202 f 1139 (304600) 
*Maximal inspiratory pressure; I-maximal expiratory pressure. 
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TABLE 3. Relationships between HAD scores for depression and relevant parameters 
95% confidence 
Odds ratio interval 
Age (>70 vs. 170)* 
Gender (male vs. female) 
FEV,% (~35% vs. >35% of predicted)* 
Dyspnoea scores 
2.9 0.92-9.17 
1.98 0.58-6.81 
0.96 0.32-9.98 
Borg score (~2 vs. >2/10)* 
Oxygen-cost diagram (~45 vs. 245)” 
Average daily distance walked ~840 vs. 2 840 m day - ‘* 
Number of days spent in hospital within past year > 15 vs. I 15 days per year* 
*Cut-off values are median values; tP<O.O5. 
0.54 0.17-1.7 
0.38 0.13-1.13 
4.67 1.39-l 5.41 
5.3 1.7-16.3? 
follow the recommended prescription of at least 15 h 
day-‘. Overall compliance to treatment, as pre- 
viously defined, was therefore 65%. There was an 
inverse correlation between average daily distance 
walked and number of hours under oxygen therapy 
(r=0.372, P=O.O02). 
FOLLOW-UP EVALUATION 
Of the initial 79 patients, 24 (30.5%) had died during 
the follow-up period, three had stopped using oxygen 
(4%) 13 (16%) declined to participate to the second 
part of the study, five (6%) were clinically unstable, 
and two patients could not be reached. One-year 
survival was 69%. 
None of the parameters tested had a predictive 
value in terms of mortality; no significant differences 
were found between survivors and patients deceased 
in terms of sex, age, initial PFT, average daily dis- 
tance walked, body-mass index, dyspnoea, HAD 
scores and QL-index scores. Thirty-two patients 
were re-assessed approximately 1 yr after the initial 
evaluation (385 i 84 days). 
No significant change had occurred in any of the 
parameters measured. Prevalence of anxiety and 
depressive disorders was unchanged in the 32 patients 
re-assessed, and did not differ with that observed for 
the initial 79 patients h2). 
RELATIONSHIP BETWEEN DYSPNOEA SCORES 
AND PFT 
Resting dyspnoea (Borg scale) 
No significant relationship was found between resting 
dyspnoea ratings and PFTs, SaO,, average daily 
distance walked, or compliance to treatment. 
Exertional dyspnoea (oxygen-cost diagram] 
The oxygen-cost diagram gives a subjective rating 
of the maximal effort that a patient can sustain 
without being limited by dyspnoea. Scores were 
significantly correlated with average daily distance 
walked (rhoz0.45, P=O.O003); there was a weaker 
correlation between oxygen-cost diagram and FEV, 
(rho =0.27, P=O.O2) or FEV,/CVF (rho =0.23, 
P= 0.05). 
RELATIONSHIP BETWEEN HRQL SCORES 
AND PFT 
HAD scores for unxiety (HAD A) 
HAD A scores showed a weak correlation with SaO, 
(rho= - 0.27, P=O.O02), but no other significant 
relation with other PFTs, average daily distance 
walked, or dyspnoea scores. Age and gender were not 
related to anxiety scores; however, time spent in 
hospital was (rho = 0.32, P=O.O02). 
HAD scores for depression [HAD D: Table 3) 
HAD D scores were not related to age nor gender. 
Nor were they related to FEV,, SaO,, or dyspnoea 
scores. However, there was a significant relationship 
between presence of a depressive disorder (HAD D 
2 1 l), and number of days spent in hospital over the 
preceding year (rho=0.34, P=O.O04). There was also 
an inverse relationship between average daily distance 
walked and presence of a depressive disorder 
(rho=0.44, P=O.O004). 
QL-index 
Estimation of quality of life by attending physician 
(QL-index) was significantly related only to HAD 
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TABLE 4. Correlations between the St George Respiratory Questionnaire (SGRQ) and relevant parameters 
Symptoms Activity 
n=32 n=32 
Impact 
n=32 
Total 
n=32 
Age 
FEV, (% of predicted) 
Average daily distance walked 
SaO, (room air) 
Borg (resting dyspnoea) 
Oxygen-cost diagram 
HAD scores for anxiety 
HAD scores for depression 
Number of days spent in hospital within past year 
0.23 0.44” 0.31 
0.18 0.03 ( - )0.06 (- )K 
( - )0.27 ( - )0.59-f (-)0.51” ( - )0.55? 
0.11 ( - )O.OS ( - )0.02 ( - )0.02 
0.43” 0.657 0.58? 
(-):.:6* ( - )0.67$ ( - )0.77$ ( - )0.78$ 
0.21 0.36” 0.46” 0.44” 
0.47? 0.621 0.63$ 0.686 
0.61% 0.29 0.51? 0.50? 
Spearman’s rank correlations: *P<O.O5; j-PcO.01; $P<O.OOl. 
scores for depression [OR=5.87, 95% CI: (1.6-21.5)], 
and to average daily distance walked [OR= 14.5, 95% 
CI: (3.44-60.8)]. QL-index did not show any sig- 
nificant relationship with dyspnoea scores or HAD 
anxiety scores. 
St George’s Respivatouy Questionnaire (median values 
and range) (Table 4) 
SGRQ was performed in 32 of the initial 79 patients; 
as previously mentioned, these patients did not show 
any significant difference with the initial cohort in 
terms of severity of impairment, or prevalence of 
anxiety and depression, and were considered rep- 
resentative of the initial group. SGRQ score for 
‘symptoms’ was 52 (range: 20-76). The ‘symptom’ 
score relates mainly to daily cough and sputum 
production and wheezing; it was not significantly 
related to age, FEV,%, average daily distance walked, 
or SaO,. It showed the weakest correlations with 
dyspnoea and HAD scores. 
SGRQ score for ‘activity’ gave very high values 
(79; range: 36-loo), meaning strong limitation of 
activity. This item correlated well with age, average 
daily distance walked, and oxygen-cost diagram 
(exertional dyspnoea). It was also strongly related to 
HAD scores for depression, and showed a weaker 
relationship to HAD scores for anxiety and resting 
dyspnoea. 
SGRQ score for ‘impact’ was 50 (range: 4-88). The 
only physiological parameter significantly related to 
this item was average daily distance walked. Dysp- 
noea and HAD scores were more strongly related to 
the ‘impact’ score than to any of the other SGRQ 
items. Total SGRQ score was 59 (range: 19-88). 
Parameters significantly related to number of days spent 
in hospital 
No functional parameter other than average daily 
distance walked (rho= - 0.31; P=O.O02) was signifi- 
cantly correlated with the number of days spent in 
hospital within the past year. This was also the case 
for age and gender. However, time spent in hospital 
was significantly correlated with HAD scores for 
anxiety and depression, and with SGRQ scores 
for ‘Symptoms’ and ‘Impact’ (Tables 3 and 4). 
Discussion 
The present study describes physiological parameters 
and health-related quality of life (HRQL) of 79 
patients under LTOT, and their evolution over a 1-yr 
period. 
Patients studied showed major physical impair- 
ment related to their respiratory illness: 46% of 
patients walked less than 600 m day - ’ (Fig. 3); 22% 
suffered from moderate to strong resting dyspnoea 
(Fig. 1); hospitalizations were frequent (54% within 
the past year, with an average of 51 + 53 days spent in 
hospital per patient per year). HAD scores suggested 
a high prevalence of depressive and anxiety disorders 
(21 and 27%, respectively). After 1 yr, survival rate 
was 69%. Prevalence of emotional disturbance, physi- 
cal impairment and resting dyspnoea remained 
unchanged. 
These data suggest that the HRQL of patients 
under LTOT is poor; evaluation of quality of life by 
attending physicians corroborates this observation: 
average QL-index scores were low, 55% of patients 
had scores <50/100. Interestingly, the average daily 
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distance walked, as an index of physical impairment, 
and the number of days per patient spent in hospital 
were the only items consistently related with HRQL 
scores and particularly with the presence of depres- 
sive disorders (Tables 3 and 4). 
Long-term oxygen therapy is a significant public 
health issue: in Western Europe, prevalence of 
patients under LTOT is between 20 and 50 per 
100 000 inhabitants, and up to 360 per 100 000 in- 
habitants in the U.S.A. (28-32). Estimations of 
annual cost of LTOT per patient range from 
U.S.$lSOO to 7300, depending on the type of source 
used for oxygen delivery (30,32,33). Such a cost seems 
justified by the clearly established benefit on survival 
for these patients. However, the quality of life of these 
patients - at least as much as their survival ~ should 
also be of some concern. 
LTOT: NO EFFECT ON QUALITY OF LIFE? 
The present study aimed to describe the quality of life 
of patients under LTOT: it was not designed to 
quantify possible changes in quality of life induced 
by LTOT. Indeed, few studies have addressed the 
specific question of HRQL in patients under LTOT. 
Heaton et al. (8) studied 150 COPD patients of the 
Nocturnal Oxygen Therapy Trial: the initial evalu- 
ation showed major emotional distress and impaired 
quality of life prior to the initiation of oxygen treat- 
ment. After 12 months, under continuous or noctur- 
nal oxygen therapy, no group did significantly better 
on quality of life measures when compared to 
matched controls. McSweeny et al. (11) studied 203 
patients of the Nocturnal Oxygen Therapy Trial: the 
Sickness Impact Profile scores (a generic HRQL 
instrument) showed severe impairment in all domains 
tested; recreational activities, home management and 
quality of sleep were the most severely affected. 
Interestingly, relationships between Sickness Impact 
Profile scores and pulmonary function tests or PaO, 
did not reach statistical significance. Strom et al., also 
using the Sickness Impact Profile in 41 patients under 
LTOT, found their quality of life severely impaired; 
most patients furthermore felt restricted by the 
oxygen treatment (29). 
The Medical Research Council study (3) showed no 
significant differences in the number of days spent 
in hospital between the treated and control groups. 
This is an important point since the present study 
suggests that the number of days spent in hospital is a 
relevant parameter for assessing quality of life, and is 
significantly related to the presence of depressive 
disorders. 
To date, therefore, although it is clearly established 
that LTOT improves survival, no study has clearly 
demonstrated a benefit of LTOT in terms of HRQL 
in hypoxic patients suffering either from COPD, or 
restrictive disorders. Furthermore, available data 
suggest a strong HRQL impairment in these 
patients. Minor improvements in neuropsychological 
functions, however, can be expected (8). 
ANXIETY AND DEPRESSION: HIGH 
PREVALENCE IN PATIENTS WITH 
RESPIRATORY IMPAIRMENT 
As previously mentioned, 27% of patients in the 
present study suffered from depressive disorders and 
21% from anxiety disorders. Others have reported 
depression rates of 28-74%, and disabling anxiety in 
up to 96% of patients (11,34,35). The prevalence of 
emotional disorders is most probably underestimated 
in the present study because of the cut-off value 
chosen for determining cases and non-cases (2 11) 
(21). When compared to the general population, these 
results ~ and those of others - suggest a strong associ- 
ation between hypoxic COPD and anxiety or depres- 
sion (36). Indeed, the 6-month prevalence of anxiety 
disorders is approximately 19% in the ‘>65’ age 
group, in the general population, and somewhat 
lower for middle-aged (45-64) adults (37). As for 
depression, studies have estimated that major depres- 
sion occurs in 2-4% of persons in the community, 
5-10% of primary care patients, and lo-14% of 
medical inpatients (38). Most studies give point 
prevalence rates of depression for the adult popu- 
lation between 3 and 4% (39). Depression in COPD 
appears, therefore, much more frequently than in the 
general population. The authors do not know of any 
studies addressing this issue in non-COPD hypoxic 
patients under LTOT. In the present study, preva- 
lence of anxiety or depressive disorders did not differ 
between COPD and non-COPD patients. 
Scores for depression were significantly related to 
physical mobility: indeed, patients with the most 
severe physical impairment had the highest pro- 
portion of depressive disorders. We cannot establish 
if the restriction in motility is a reflection of depres- 
sion, or if depression is reactive to physical impair- 
ment. However, recent publications suggest a benefit 
on quality of life of home rehabilitation programmes 
(40,41), and a relationship between HRQL scores and 
gain in exercise tolerance (40). Rehabilitation on an 
outpatient basis might have a beneficial effect on 
selected patients, although expectations as to major 
changes in exercise tolerance achievable in hypoxic 
COPD patients are modest. Oxygen for ambulation 
may also prove to be contributive to improve HRQL 
in selected patients. 
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Sixty-five percent of the patients studied complied 
to the initial prescription ( 2 15 h day - ‘). This com- 
pliance rate is higher than that reported by other 
European studies: 25-62% (33,4245); it is also higher 
than previously reported by the authors’ group in the 
same area (13), suggesting a positive effect of the 48-h 
training given to all patients under LTOT. 
SPECIFIC CONTRIBUTION OF HRQL 
INSTRUMENTS 
In the present study, the Borg scale, the oxygen-cost 
diagram, the Hospital anxiety and Depression scale 
(HAD), and the St George Respiratory Questionnaire 
(SGRQ) were used as HRQL instruments. The Borg 
scale, the oxygen-cost diagram and the SGRQ are 
considered disease-specific HRQL instruments (12). 
HAD, although being a tool for quantifying mood 
disorders rather than quality of life, would be 
considered a generic instrument. 
Resting dyspnoea (Borg scale) showed no signifi- 
cant relationship with PFTs, PI or PE max, average 
daily distance walked or SaO,. Clearly, measuring 
resting dyspnoea gave information that could not be 
extrapolated from traditional measures. Interestingly, 
no significant relationship was found between resting 
dyspnoea scores and anxiety, exertional dyspnoea 
(oxygen-cost diagram), or compliance to treatment. 
The oxygen-cost diagram (20) gave a reliable evalu- 
ation of subjective exercise tolerance: it was very 
significantly correlated with average daily distance 
walked (rho=0.45, P= 0.0003). McGavin et al. had 
previously noted very significant correlations between 
1Zmin walking tests and the oxygen-cost diagram in 
patients with COPD or ILD (20). Subjective exercise 
tolerance, as assessed by the oxygen-cost diagram, 
could not be extrapolated from resting dyspnoea 
measurements. 
The SGRQ score is a disease-specific HRQL instru- 
ment considered to be reproducible, valid and respon- 
sive (12). It quantifies symptoms related to airway 
disease, and impact of respiratory disease on daily 
activities and social functioning. Jones et al. excluded 
questions explicitly designed to assess anxiety and 
depression. Correlation with PFTs is known to be 
low; correlation with 6 min walk tests and with 
dyspnoea scores is expected to be the highest with the 
‘Activity’ and ‘Impact’ scores (23,24,46). The present 
data are in agreement with these observations: daily 
distance walked was the only functional parameter 
significantly related to SGRQ scores (Table 4); the 
SGRQ stressed the importance of physical mobility 
on health-related quality of life in this group of 
patients, and the lack of significance of FEV, or SaO, 
as to quantifying HRQL. Furthermore, the strong 
correlation between the number of days spent in 
hospital and SGRQ scores corroborates the corre- 
lation previously described with the presence of 
depression, or QL-index ratings. 
Conclusion 
The data presented suggest that hypoxic patients 
under LTOT have on average a poor quality of life: 
their morbidity and mortality is high, they suffer from 
high rates of emotional disturbances, and diminished 
physical mobility. In order to enhance the possible 
benefit of LTOT on quality of life or general well- 
being, emphasis should be placed on outpatient long- 
term pulmonary rehabilitation programmes and use 
of portable oxygen devices to maintain or increase 
physical mobility, and on appropriate support and 
treatment for emotional disturbances in patients 
under LTOT. 
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